Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Henan Taloph Pharmaceutical Stock Co (SHSE:600222) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Henan Taloph Pharmaceutical Stock Co EBITDA Margin % Related Terms
Henan Taloph Pharmaceutical Stock Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Taloph Pharmaceutical Stock Co EBITDA Margin % Chart
SHSE:600222 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Henan Taloph Pharmaceutical Stock Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Henan Taloph Pharmaceutical Stock Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Henan Taloph Pharmaceutical Stock Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Henan Taloph Pharmaceutical Stock Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Taloph Pharmaceutical Stock Co (SHSE:600222) has a EBITDA Margin % of 4.70% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Henan Taloph Pharmaceutical Stock Co and its competitors. This is 52% below median its historical median of 9.70. Over the past decade, Henan Taloph Pharmaceutical Stock Co's EBITDA Margin % has ranged from 0.73 to 13.43. According to the industry distribution chart, Henan Taloph Pharmaceutical Stock Co ranks #596 out of 961 companies in the Drug Manufacturers industry, placing it in the top 62%.
Is Henan Taloph Pharmaceutical Stock Co's EBITDA Margin % too high?
Henan Taloph Pharmaceutical Stock Co's current EBITDA Margin % of 4.70% is 52% below median its 10-year median of 9.70. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 13.43. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Henan Taloph Pharmaceutical Stock Co's value of 4.70% is 62.4% below this industry median. Based on the distribution chart, Henan Taloph Pharmaceutical Stock Co ranks #596 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Henan Taloph Pharmaceutical Stock Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Henan Taloph Pharmaceutical Stock Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Henan Taloph Pharmaceutical Stock Co ranks #596 out of 961 companies for EBITDA Margin %. This places Henan Taloph Pharmaceutical Stock Co in the lower half of its industry. The industry median EBITDA Margin % is 12.49. Henan Taloph Pharmaceutical Stock Co's value of 4.70% is 62.4% below this benchmark. Historically, Henan Taloph Pharmaceutical Stock Co's own EBITDA Margin % has ranged from 0.73 to 13.43 over the past decade. While the company's 10-year median is 9.70 vs. the industry median of 12.49, Henan Taloph Pharmaceutical Stock Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Henan Taloph Pharmaceutical Stock Co's current EBITDA Margin % of 4.70% is 62.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Henan Taloph Pharmaceutical Stock Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Henan Taloph Pharmaceutical Stock Co's current EBITDA Margin % is 4.70%, which is 52% below median its own 10-year median of 9.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Taloph Pharmaceutical Stock Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co (SHSE:600222) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.92, compared to a current price of ¥7.45 — trading 51.4% above its estimated fair value. The current EBITDA Margin % is 4.70%, which is 52% below median its 10-year median of 9.70 and 62.4% below the Drug Manufacturers industry median of 12.49. Henan Taloph Pharmaceutical Stock Co's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Henan Taloph Pharmaceutical Stock Co (SHSE:600222), the current EBITDA Margin % is 4.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Overvalued in 2026?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co stock appears to be overvalued.
The current stock price of ¥7.45 is trading 51.4% above its estimated GF Value™ of ¥4.92.
GuruFocus considers Henan Taloph Pharmaceutical Stock Co to be Significantly Overvalued.
Key valuation signals for SHSE:600222:
EBITDA Margin %: 4.70% (52% below median its 10-year median of 9.70)
GF Value™: ¥4.92 vs. price of ¥7.45 (51.4% above fair value)
Industry Position: 62.4% below the Drug Manufacturers median (#596 of 961)
No single metric tells the full story. See the SHSE:600222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Henan Taloph Pharmaceutical Stock Co Business Description
Henan Taloph Pharmaceutical Stock Co Ltd is a Chinese company engaged in pharmaceutical manufacturing and pharmaceutical research and development services, including pharmaceutical preparations, Chinese herbal medicine slices, and pharmaceutical research and development services. The company's pharmaceutical preparation business is mainly based on oral Chinese medicine preparations, and its treatment areas cover the respiratory system, cardiovascular and cerebrovascular system, digestive system, and nervous system.
58GF Score
Get the complete analysis for SHSE:600222
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600222 has been successfully added to your 
